Tenofovir Disoproxil Fumarate Efavirenz and Emtricitabine tablets

Product Description

The combination of Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV), and Emtricitabine (FTC) is a widely used antiretroviral medication for the treatment of HIV-1 infection. This combination is often provided in a fixed-dose tablet to simplify the treatment regimen for individuals living with HIV.

Here are some key points about Tenofovir Disoproxil Fumarate, Efavirenz, and Emtricitabine tablets:

1. Tenofovir Disoproxil Fumarate (TDF):

   • TDF is a nucleotide reverse transcriptase inhibitor (NRTI).
   • It inhibits the reverse transcriptase enzyme, preventing the replication of the HIV virus.

2. Efavirenz (EFV):

   • EFV is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
   • It works by binding to and inhibiting the reverse transcriptase enzyme, disrupting the replication of the HIV virus.

3. Emtricitabine (FTC):

   • FTC is a nucleoside reverse transcriptase inhibitor (NRTI).
   • It inhibits the reverse transcriptase enzyme, disrupting the replication of the HIV virus.

Key points about the combination (Tenofovir Disoproxil Fumarate, Efavirenz, and Emtricitabine tablets):

• Indications: This combination is used for the treatment of HIV-1 infection in adults and pediatric patients.

• Dosage: The typical dosage involves taking one tablet orally once daily. The specific dosage may vary depending on the individual's health condition and the overall HIV treatment plan prescribed by a healthcare professional.

• Adherence: Consistent adherence to the prescribed regimen is crucial for the effectiveness of HIV treatment. Missing doses or not taking the medication as directed can lead to reduced efficacy and the development of drug resistance.

• Side Effects: Potential side effects may include nausea, headache, and fatigue. It's important to report any severe or persistent side effects to a healthcare provider.

• Pregnancy: The use of this combination during pregnancy should be discussed with a healthcare provider, taking into consideration the potential risks and benefits.

Individuals prescribed with this combination should follow the guidance of their healthcare provider, undergo regular monitoring, and communicate any concerns or side effects experienced during the treatment. As always, individual circumstances may vary, and healthcare providers can provide personalized information based on the patient's medical history and needs

Effective Antiretroviral Combination

This medication brings together three potent agents-Tenofovir Disoproxil Fumarate, Efavirenz, and Emtricitabine-in a single, daily tablet that targets HIV-1 at multiple stages of its lifecycle. The fixed-dose approach improves adherence and is recommended by major treatment guidelines for adults and adolescents. It provides effective viral suppression, helping patients achieve better health outcomes while minimizing pill burden.


WHO Prequalified & Broadly Approved

Manufactured under strict quality controls, these tablets are WHO prequalified and approved in India as well as various international markets. They meet established global standards, offering reliability to dealers, distributors, and health organizations worldwide. The product is suitable for export and widespread distribution through multiple supply channels, supporting public health initiatives.


Convenient Packaging and Administration

The tablets are supplied in protective Alu-Alu blister packs or HDPE bottles, with each pack containing 30 tablets. Designed for once-daily oral administration, the product provides convenience for both patients and healthcare providers. The robust packaging helps ensure stability and prevents exposure to moisture or light, maintaining efficacy throughout the shelf life.